Alberto Escallon
Psychiatry · Yonkers, NYNPI 1184818452
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 607 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,872 and has fallen 59.3% since, to $1,169 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 607 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$1K
- Tris Pharma Inc$1K
- Neos Therapeutics, LP$774
- Takeda Pharmaceuticals U.S.A., Inc.$770
- plus $4K from 23 others
What the payments were for
- Food & beverage$10,502100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 77 | $1,508 |
| Otsuka America Pharmaceutical, Inc. | 76 | $1,310 |
| Lundbeck LLC | 75 | $1,224 |
| Tris Pharma Inc | 64 | $1,101 |
| Neos Therapeutics, LP | 52 | $774 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $770 |
| Supernus Pharmaceuticals, Inc. | 43 | $719 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $602 |
| Arbor Pharmaceuticals, Inc. | 31 | $554 |
| Corium, LLC | 18 | $337 |
| Sunovion Pharmaceuticals Inc. | 17 | $268 |
| Shire North American Group Inc | 19 | $237 |
| Axsome Therapeutics, Inc. | 7 | $151 |
| Vertical Pharmaceuticals, LLC | 7 | $129 |
| Johnson & Johnson | 6 | $117 |
| Ironshore Pharmaceuticals Inc. | 6 | $116 |
| Collegium Pharmaceutical, Inc. | 4 | $79 |
| Adlon Therapeutics L.p. | 4 | $74 |
| Almatica Pharma LLC | 3 | $67 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $66 |
| Neurocrine Biosciences, Inc. | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Bausch Health US, LLC | 2 | $39 |
| Noven Therapeutics, LLC | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Alfasigma USA, Inc. | 2 | $31 |
| Alkermes, Inc. | 1 | $23 |
| Sage Therapeutics, LLC | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$160
How this compares
$10,502 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $523 |
| Citalopram HbrCitalopram Hydrobromide | 12 | $18 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Yonkers
- Yadagiri ChepuruYonkers$963K
- Yugandhar MunnangiYonkers$259K
- David DickoffYonkers$112K
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.